Skip to main content

Day: October 28, 2024

Telesat and Airbus begin collaboration to integrate Telesat Lightspeed services into HBCplus portfolio

LONG BEACH, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) — APEX Expo — Telesat (NASDAQ and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced the signing of a Memorandum of Understanding (MOU) with Airbus SAS to collaborate on the integration of the Telesat Lightspeed low earth orbit (LEO) network within the Airbus HBCplus Ka-band solution portfolio. Airbus launched its HBCplus satellite connectivity solution as a supplier-furnished line-fit catalogue option and also for retrofit on all Airbus programs. Airbus and Telesat will work together to address user terminal integration for HBCplus installations that are capable of providing Telesat Lightspeed services. “Our advanced, enterprise-class LEO network was designed from inception to meet the demanding requirements of inflight connectivity...

Continue reading

Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

– ATEV™ demonstrated superiority at six and 12 months (co-primary endpoints) compared to autogenous fistula, the current standard of care for hemodialysis access – – ATEV also showed superior function and patency in female, obese and diabetic patients, subgroups with historically poor outcomes with autogenous fistula procedures – DURHAM, N.C., Oct. 28, 2024 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced the presentation of positive results from the V007 Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV) in arteriovenous (AV) access for patients with end-stage renal disease at the American Society of Nephrology’s (ASN) Kidney Week 2024, the premier...

Continue reading

Local News Live Announces Election Night Coverage

ATLANTA, Oct. 28, 2024 (GLOBE NEWSWIRE) —  Gray Media (NYSE: GTN) today announced comprehensive election night coverage plans on Local News Live, its 24/7 news network.   Starting at 7 p.m. EST on November 5th, Local News Live will stream election coverage on Roku, Amazon Fire, Apple TV, iOS, and Android streaming devices.   The Local News Live feed will also be carried on localnewslive.com and more than 500 Gray Media digital properties. Debra Alfarone, Rasheeda Kabba, Graham Ulkins, and Camila Rueda will anchor unmatched team coverage from Local News Live studios in Washington, D.C., with access to live reporters on the ground across 113 markets.   Additionally, White House Correspondent Jon Decker will report live from Harris campaign headquarters and Senior National Correspondent Peter Zampa will report live from Trump campaign...

Continue reading

Bitfarms Appoints Rachel Silverstein as U.S. General Counsel

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated March 8, 2024, to its short form base shelf prospectus dated November 10, 2023. TORONTO, Ontario and BROSSARD, Québec, Oct. 28, 2024 (GLOBE NEWSWIRE) — Bitfarms Ltd. (NASDAQ/TSX: BITF), a global leader in vertically integrated Bitcoin data center operations, today announced that it has appointed Rachel Silverstein as U.S. General Counsel, a newly created role, effective November 1, 2024. Ms. Silverstein has been a practicing attorney for over 16 years and is one of the most experienced Bitcoin mining-focused attorneys in the U.S., having served as lead counsel on well over a gigawatt worth of Bitcoin mining transactions across multiple states and countries. She is the co-founder of Firm 21m, a law firm dedicated...

Continue reading

NexGold Intersects Visible Gold 70 metres below a previous result of 193 g/t over 1 metre showing extension to the C Zone East area at the Goliath Deposit

TORONTO, Oct. 28, 2024 (GLOBE NEWSWIRE) — NexGold Mining Corp. (TSXV: NEXG; OTCQX: NXGCF) (“NexGold” or the “Company”) is pleased to announce that recent drilling has intersected significant visible gold located below the current mineral resource on the eastern end of the C Zone at the Goliath deposit at the Goliath Gold Complex (the “Project”). This was intersected approximately 70 metres below a past mineral occurrence of 65.2 g/t Au over 3.0 metres including 193 g/t Au over 1.0 metres.Figure 1: Visible Gold in TL24-678 Goliath Mineral Resource Expansion Drilling Program The visible gold found in drillhole TL24-678 (Figure 1) was encountered approximately 70 metres down dip of previously-released hole TL20-520 (Company news release dated March 5, 2020) which intersected 1.35 g/t Au over 14.7 metres including 6.00 g/t Au over...

Continue reading

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

– DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a gain of +8.9 letters compared to baseline – – DURAVYU 2.7mg demonstrated an early and sustained anatomical improvement mirroring BCVA results with a 68 micron reduction in CST – – Favorable safety profile continues with no DURAVYU-related ocular or systemic SAEs to date – – Full topline data anticipated in Q1 2025 – WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced positive interim 16-week data for the ongoing Phase 2 VERONA clinical trial evaluating DURAVYU, an investigational sustained delivery therapy delivering patent-protected...

Continue reading

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Agreement expected to accelerate MRT-6160 clinical development and broadly explore therapeutic opportunities across multiple indications Monte Rosa to receive up-front payment of $150 million and is eligible to receive milestone payments, U.S. profit and loss share, and tiered royalties on ex-U.S. net sales BOSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced a global exclusive development and commercialization license agreement with Novartis to advance VAV1 MGDs, including MRT-6160. MRT-6160 is currently in an ongoing Phase 1, single ascending dose (SAD)/multiple ascending dose (MAD) healthy volunteer study for immune-mediated conditions. Under the terms of the agreement, Novartis...

Continue reading

Solar Alliance signs contract for $3.7 million solar project in Kentucky

TORONTO and KNOXVILLE, Tenn., Oct. 28, 2024 (GLOBE NEWSWIRE) — Solar Alliance Energy Inc. (‘Solar Alliance’ or the ‘Company’) (TSX-V: SOLR, OTC: SAENF), a leading solar energy solutions provider focused on the commercial and utility solar sectors, is pleased to announce it has signed a contract for the design, engineering and installation of a $3.7 million solar project for a customer in Kentucky. The project consists of two sites, both scheduled to begin construction in November 2024: a 553-kilowatt (“kW”) project targeted for completion by the end of 2024 and a 943-kilowatt (“kW”) project targeted for completion by the end of March 2025. “This project is a pertinent illustration of the growth we are encountering as a company, and the trust and reputation we are building with regional customers,” said U.S. General Manager Jon...

Continue reading

PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance

SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) — PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2024. Recent HighlightsTotal revenue of $58.4 million for the third quarter of 2024, an increase of 66% compared to the prior period in 2023 U.S. handpiece and consumables revenue of $29.6 million for the third quarter of 2024, an increase of 74% compared to the prior period in 2023 Sold 45 robotic systems in the U.S. in the third quarter of 2024 at an average selling price of approximately $432,000 U.S. system and rental revenue of $19.6 million for the third quarter of 2024, an increase of 46% compared to the prior period...

Continue reading

Nova Minerals Attending the ThinkEquity Conference In New York on October 30, 2024

Caufield, Australia, Oct. 28, 2024 (GLOBE NEWSWIRE) — Nova Minerals Limited (“Nova” and the “Company”) (NASDAQ: NVA) (ASX: NVA) (FRA: QM3), a gold and critical minerals exploration stage company focused on advancing the Estelle Gold Project in Alaska, U.S.A., is pleased to advise that our team will be presenting at the ThinkEquity conference in New York, USA, on October 30, 2024. In addition to the conference attendance, the team will also be conducting a road show in New York for US investors this week. A PDF version of the presentation is attached to this announcement, and a Vrify 3D interactive version of the presentation, which now also includes the 2024 drilling results, can be found on the Company’s website at: https://novaminerals.com.au/investors/us-investors-3d-vrify-thinkequity-conference-presentation/ About Nova Minerals...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.